AI has transformed patient identification, but a data match is only the first step. Real-world experience shows that enrollment depends on converting matches into informed, engaged participants through site workflows, physician trust, and patient support. This session explores combining data-driven matching, community partnerships, and human-centered navigation to bridge the gap between identification and consent, creating an effective model for recruitment.

What happens when a potential participant’s first interaction with clinical research is a conversation with AI? As public AI platforms change how people seek and navigate information, the clinical research community must consider our role in shaping this evolving experience. This presentation explores public and sponsor-owned AI as a new “front door” to clinical research. Drawing on real-world experience evaluating patient-facing AI, we’ll examine its potential to reshape trial discovery, recruitment, and participant engagement, while exploring the opportunities, risks, and responsibilities that emerge when AI interacts directly with potential participants, including considerations around trust, transparency, safety, governance, and responsible innovation.

How can sponsors partner with sites earlier in recruitment planning? This session explores how sponsors and sites can build recruitment strategies together by investing upfront in two-way conversations about site readiness, capacity, and the time needed to screen the first participant. Engaging sites as key stakeholders from the outset helps establish realistic enrolment goals, identify support needs, and build shared accountability for delivery. That dialogue must continue from start-up through the end of enrolment, creating opportunities to address challenges and adapt as conditions change. Discover how sustained collaboration can turn shared recruitment goals into achievable results.

We present an AI/ML-driven clinical trial analytics platform designed to improve retention in large, event-driven studies. By combining participant, site, and real-time operational data, the solution generates monthly dropout risk scores that identify participants most likely to discontinue, achieving approximately 2× higher detection of at-risk participants than missed-visit monitoring alone. These insights enable proactive, targeted retention interventions and more efficient trial execution.

Clinical trial recruitment and retention remain persistent challenges, often linked to gaps in participant understanding. This panel examines how locally deployable AI tools support participant education and communication throughout the trial process. Unlike cloud-based tools, this approach preserves privacy by performing inference locally. Panelists will discuss the tool's design, deployment, and potential to improve recruitment, retention, and participant satisfaction.

AI tools for patient identification, pre-qualification, and engagement have multiplied, but evidence of their impact on enrollment timelines remains uneven. This panel brings together sponsor leaders to share what they require before adopting AI in recruitment, where these tools have delivered measurable gains, where they've fallen short, and how organizations are evaluating impact beyond match rates. Panelists will discuss integration with site workflows, patient trust and transparency, and the metrics that matter when deciding what to scale.

AbbVie is evolving from a submission-focused approach toward a globally informed, execution-oriented model for representative enrollment. This session will explore AbbVie's emerging Global Patient Access Plan (GPAP) and Study-Level Inclusion Plan (SLIP) framework, which links disease-specific demographic and disparity insights with study-level enrollment strategies and operational action plans. Presenters will discuss how strategic planning, functional accountability, risk management, and enrollment monitoring can work together to make inclusion measurable, actionable, and embedded throughout clinical development.

Readability scores of written materials often mask true accessibility, creating a false sense of security. This session details a breakthrough multi-party collaboration between the Pfizer and the UK's NIHR and National Literacy Trust that moved beyond automated metrics to co-design trial materials directly with low-literacy communities. By exposing misinterpreted imagery and the "inference gap" in standard templates, we provide a community-proven, operational framework to ensure genuine informed consent, equitable participation, and compliance with evolving global regulatory requirements.

Informed consent forms (ICFs) are intended to help prospective participants understand a clinical trial and make informed decisions about participation. Yet, many ICFs remain lengthy, complex, and difficult for patients to navigate. This session will feature a case study that demonstrates the importance of health literacy and patient feedback in creating an accessible and effective ICF.  Key recommendations based on in-depth health literacy assessment and patient feedback included reformatting, simplifying graphics, and leading with empathy. Lessons learned will help sponsors and other stakeholders develop ICFs that better support understanding and informed decision-making.

As patient-related services continue to expand, organizations face increasing pressure to demonstrate both patient and business value. This presentation shares lessons learned from implementing a ROI-based assessment framework for vendor-supported patient services. By combining financial, operational, and outcome-based measures, the approach enabled more objective decision-making and portfolio optimization. The analysis uncovered multi-million-dollar opportunities for efficiency improvements while highlighting programs that delivered disproportionate value to patients and the organization. The session will also provide insights from an emerging patient wellbeing pilot, illustrating how organizations can broaden their focus from service delivery to the overall patient experience. Participants will leave with practical ideas for building a sustainable measurement framework that transforms patient service investments into demonstrable strategic assets.

Community engagement continues to evolve from a peripheral activity to a strategic priority for sponsors, research sites, advocacy organizations, and community-based partners seeking to improve trust, awareness, representation, and participation in clinical research. As investment and activity have increased, stakeholders strive to refine frameworks for meaningful engagement, impact measurement, and effective community relationship building. This session examines the current state in this space, highlighting emerging practices, lessons learned, and persistent challenges. Attendees will gain practical insights from real-world examples and experiences spanning community and site partnerships, educational outreach, community educator models, co-development approaches, and mobile and event-based engagement, as speakers explore how organizations are moving beyond transactional outreach toward more authentic, long-term relationships.

This session will highlight how AbbVie is leveraging the AbbVie Research Collaborative (ARC) as a scalable patient engagement ecosystem to integrate the patient voice throughout the drug development lifecycle. ARC enables ongoing partnerships with patients through surveys, patient councils, advisory panels, and study invitation opportunities, creating multiple pathways to gather patient insights and apply them to protocol development, study design, recruitment, retention, and patient experience initiatives. The presentation will showcase how sustained patient engagement can move beyond transactional interactions to inform more patient-centered clinical development strategies.

Clinical trial participants currently have little to no access to their individual study data, despite longstanding patient interest in receiving this information. Returning participant data presents several challenges, including navigating regulatory requirements, data privacy considerations, and communicating complex information in a clear, meaningful, and accessible way. This session will focus on how companies are working towards returning individual data to patients and how the patient voice can help shape these initiatives. Attendees will leave with actionable strategies for incorporating patient perspectives into future data return initiatives.